A new AHA scientific statement warns that cardiovascular disease is rising fastest among younger women, with stroke rates in ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...

Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...

A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.

Chronic kidney disease is associated with a significantly increased risk for workforce detachment among adults of working age, a Danish study finds.

A new consensus statement from the American Society of Clinical Psychopharmacology offers guidance on when — and whether — to discontinue psychotropic medications.

Cardiovascular mortality among US adults with obesity tripled from 1999 to 2023, with persistent and widening disparities across certain sociodemographic and geographic groups.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.